Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial

被引:0
作者
Roger T. Anderson
Robert W. Baran
Pennifer Erickson
Dennis A. Revicki
Birgitta Dietz
Katherine Gooch
机构
[1] Pennsylvania State University,Hershey Medical Center
[2] AbbVie,Global Health Economics and Outcomes Research
[3] OLGA,Outcomes Research
[4] United BioSource Corporation,Department of Public Health Sciences, College of Medicine
[5] AbbVie Deutschland GmbH and Co.,undefined
[6] Penn State Milton S. Hershey Medical Center,undefined
来源
Quality of Life Research | 2014年 / 23卷
关键词
Psychometric methods; Questionnaires; Health status; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:877 / 886
页数:9
相关论文
共 78 条
[1]  
Smith BD(2012)Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965 MMWR Recomm Rep 61 1-36
[2]  
Morgan RL(2010)Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 513-521
[3]  
Beckett GA(1999)Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The interventional therapy group Hepatology 30 550-555
[4]  
Davis GL(2007)The effects of HCV infection and management on health-related quality of life Hepatology 45 806-816
[5]  
Alter MJ(2012)Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection Journal of Gastroenterology and Hepatology 27 149-157
[6]  
El-Serag H(2010)Humanistic and economic impacts of hepatitis C infection in the United States Journal of Medical Economics 13 709-718
[7]  
Poynard T(2009)Diagnosis, management, and treatment of hepatitis C: An update Hepatology 49 1335-1374
[8]  
Jennings LW(2005)Estimation of utilities for chronic hepatitis C from SF-36 scores American Journal of Gastroenterology 100 643-651
[9]  
Ware JE(2007)Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders Liver International 27 1217-1225
[10]  
Bayliss MS(2004)The impact of peginterferon alfa-2a plus RBV combination therapy on health-related quality of life in chronic hepatitis C Journal of Hepatology 40 675-681